We are live on ! Find out more
OPRX icon

OptimizeRx

146 hedge funds and large institutions have $426M invested in OptimizeRx in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 66 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

664% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $2.96M

74% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1.19% less ownership

Funds ownership: 86.79%85.6% (-1.2%)

5% less funds holding

Funds holding: 153146 (-7)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

27% less capital invested

Capital invested by funds: $585M → $426M (-$159M)

Holders
146
Holders Change
-7
Holders Change %
-4.58%
% of All Funds
2.45%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
21
Increased
66
Reduced
38
Closed
25
Calls
$22.7M
Puts
$2.96M
Net Calls
+$19.7M
Net Calls Change
+$12.8M

OPRX Hedge Fund Activity: Q2 2022 in Review

146 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2022, worth a combined $426M — down 27% from $585M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of OPRX and 21 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 66 added.

The largest buyer was Kornitzer Capital Management, opening a new position worth an estimated $6.83M. The largest seller was Driehaus Capital Management, cutting an estimated $4.24M.

  • 146 institutional investors held OptimizeRx (OPRX) as of Q2 2022, down from 153 in Q1 2022.
  • Funds reported $426M of OptimizeRx stock for Q2 2022, down 27% quarter-over-quarter.
  • 21 funds opened new OptimizeRx positions in Q2 2022 and 25 closed out, a net change of -4 holders.
  • The largest OptimizeRx buyer in Q2 2022 was Kornitzer Capital Management, an estimated $6.83M added.
  • The largest OptimizeRx seller in Q2 2022 was Driehaus Capital Management, an estimated $4.24M sold.

Based on aggregated 13F filings for Q2 2022.